Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2017 2
2018 6
2019 13
2020 12
2021 3
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Crohn's disease.
Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Roda G, et al. Among authors: argollo m. Nat Rev Dis Primers. 2020 Apr 2;6(1):22. doi: 10.1038/s41572-020-0156-2. Nat Rev Dis Primers. 2020. PMID: 32242028 Review.
TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
Furfaro F, Alfarone L, Gilardi D, Correale C, Allocca M, Fiorino G, Argollo M, Zilli A, Zacharopoulou E, Loy L, Roda G, Danese S. Furfaro F, et al. Among authors: argollo m. Curr Drug Targets. 2021;22(7):760-769. doi: 10.2174/1389450122999210120205607. Curr Drug Targets. 2021. PMID: 33475057 Review.
Comorbidities in inflammatory bowel disease: a call for action.
Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, Danese S. Argollo M, et al. Lancet Gastroenterol Hepatol. 2019 Aug;4(8):643-654. doi: 10.1016/S2468-1253(19)30173-6. Epub 2019 Jun 3. Lancet Gastroenterol Hepatol. 2019. PMID: 31171484 Review.
Modulation of sphingosine-1-phosphate in ulcerative colitis.
Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, Danese S. Argollo M, et al. Expert Opin Biol Ther. 2020 Apr;20(4):413-420. doi: 10.1080/14712598.2020.1732919. Epub 2020 Feb 25. Expert Opin Biol Ther. 2020. PMID: 32093531 Review.
JAK selectivity: more precision less troubles.
Roda G, Dal Buono A, Argollo M, Danese S. Roda G, et al. Among authors: argollo m. Expert Rev Gastroenterol Hepatol. 2020 Sep;14(9):789-796. doi: 10.1080/17474124.2020.1780120. Epub 2020 Jun 16. Expert Rev Gastroenterol Hepatol. 2020. PMID: 32520647 Review.
Vedolizumab for the treatment of Crohn's disease.
Argollo M, Fiorino G, Peyrin-Biroulet L, Danese S. Argollo M, et al. Expert Rev Clin Immunol. 2018 Mar;14(3):179-189. doi: 10.1080/1744666X.2018.1438189. Epub 2018 Feb 23. Expert Rev Clin Immunol. 2018. PMID: 29406811 Review.
Biosimilars of adalimumab: the upcoming challenge in IBD.
Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S. Fiorino G, et al. Among authors: argollo m. Expert Opin Biol Ther. 2019 Oct;19(10):1023-1030. doi: 10.1080/14712598.2019.1564033. Epub 2019 Jan 8. Expert Opin Biol Ther. 2019. PMID: 30601098 Review.
Novel therapeutic targets for inflammatory bowel disease.
Argollo M, Fiorino G, Hindryckx P, Peyrin-Biroulet L, Danese S. Argollo M, et al. J Autoimmun. 2017 Dec;85:103-116. doi: 10.1016/j.jaut.2017.07.004. Epub 2017 Jul 12. J Autoimmun. 2017. PMID: 28711286 Review.
41 results